Undisclosed results of clinical trials

[Guest guest]

Public release date: 16-Feb-2004

[ Print This Article | Close This Window ]

Contact: Dr. Barbara Mintzes

bmintzes@...

Canadian Medical Association Journal

Undisclosed results of clinical trials

This issue of CMAJ includes two commentaries decrying the suppression of data

concerning unsafe or ineffective medication.

Jane Garland, a psychiatrist, clinical researcher and past investigator in SSRI

trials, states that negative results from SSRI trials go unpublished, while the

published evidence to support their use is flimsy at best. She calls on

physician-researchers to take a collective stand and demand disclosure of all

data.

In a related commentary, Herxheimer and Mintzes point to flawed trial design,

secrecy in the approvals process and inadequate systems for adverse drug

reporting as the mechanisms by which ineffective and unsafe drugs gain a place

in the market.

###

p. 487 Antidepressants and adverse effects in young patients: uncovering the

evidence -- A. Herxheimer, B. Mintzes

p. 489 Facing the evidence: antidepressant treatment in children and adolescents

-- E.J. Garland

Jim - Norman

" Never look at the trombones, it only encourages them. "

Strauss

[Guest guest]

Public release date: 16-Feb-2004

[ Print This Article | Close This Window ]

Contact: Dr. Barbara Mintzes

bmintzes@...

Canadian Medical Association Journal

Undisclosed results of clinical trials

This issue of CMAJ includes two commentaries decrying the suppression of data

concerning unsafe or ineffective medication.

Jane Garland, a psychiatrist, clinical researcher and past investigator in SSRI

trials, states that negative results from SSRI trials go unpublished, while the

published evidence to support their use is flimsy at best. She calls on

physician-researchers to take a collective stand and demand disclosure of all

data.

In a related commentary, Herxheimer and Mintzes point to flawed trial design,

secrecy in the approvals process and inadequate systems for adverse drug

reporting as the mechanisms by which ineffective and unsafe drugs gain a place

in the market.

###

p. 487 Antidepressants and adverse effects in young patients: uncovering the

evidence -- A. Herxheimer, B. Mintzes

p. 489 Facing the evidence: antidepressant treatment in children and adolescents

-- E.J. Garland

Jim - Norman

" Never look at the trombones, it only encourages them. "

Strauss

[Guest guest]

Public release date: 16-Feb-2004

[ Print This Article | Close This Window ]

Contact: Dr. Barbara Mintzes

bmintzes@...

Canadian Medical Association Journal

Undisclosed results of clinical trials

This issue of CMAJ includes two commentaries decrying the suppression of data

concerning unsafe or ineffective medication.

Jane Garland, a psychiatrist, clinical researcher and past investigator in SSRI

trials, states that negative results from SSRI trials go unpublished, while the

published evidence to support their use is flimsy at best. She calls on

physician-researchers to take a collective stand and demand disclosure of all

data.

In a related commentary, Herxheimer and Mintzes point to flawed trial design,

secrecy in the approvals process and inadequate systems for adverse drug

reporting as the mechanisms by which ineffective and unsafe drugs gain a place

in the market.

###

p. 487 Antidepressants and adverse effects in young patients: uncovering the

evidence -- A. Herxheimer, B. Mintzes

p. 489 Facing the evidence: antidepressant treatment in children and adolescents

-- E.J. Garland

Jim - Norman

" Never look at the trombones, it only encourages them. "

Strauss

[Guest guest]

Public release date: 16-Feb-2004

[ Print This Article | Close This Window ]

Contact: Dr. Barbara Mintzes

bmintzes@...

Canadian Medical Association Journal

Undisclosed results of clinical trials

This issue of CMAJ includes two commentaries decrying the suppression of data

concerning unsafe or ineffective medication.

Jane Garland, a psychiatrist, clinical researcher and past investigator in SSRI

trials, states that negative results from SSRI trials go unpublished, while the

published evidence to support their use is flimsy at best. She calls on

physician-researchers to take a collective stand and demand disclosure of all

data.

In a related commentary, Herxheimer and Mintzes point to flawed trial design,

secrecy in the approvals process and inadequate systems for adverse drug

reporting as the mechanisms by which ineffective and unsafe drugs gain a place

in the market.

###

p. 487 Antidepressants and adverse effects in young patients: uncovering the

evidence -- A. Herxheimer, B. Mintzes

p. 489 Facing the evidence: antidepressant treatment in children and adolescents

-- E.J. Garland

Jim - Norman

" Never look at the trombones, it only encourages them. "

Strauss